Introduction
============

Breast cancer is the most common cancer in females globally, with the incidence rate increasing 0.5% every year. In addition, a gradual trend is forming for the cancer to occur in females of a younger age and the morbidity rate is increasing, which severely threatens the health of women around the world ([@b1-ol-0-0-8836],[@b2-ol-0-0-8836]), although its precise mechanism is presently unclear. Growing evidence has suggested that the tumor microenvironment serves a role in the development of cancer and its prognosis ([@b3-ol-0-0-8836],[@b4-ol-0-0-8836]).

Cell adhesion molecules are a type of glycoprotein mediating cell-cell and cell-extracellular matrix adhesion, and they serve an important role in the genesis, development, invasion and metastasis of tumors ([@b5-ol-0-0-8836]). The decrease in tumor cell adhesion appears to easily affect tumor invasion and metastasis. Epithelial-cadherin (E-cadherin) is an important member of the cadherin family and serves an important role in the cell adhesion process. It has been reported that E-cadherin is underexpressed in a variety of tumors, and that it could participate in the growth, differentiation, metastasis and prognosis of breast cancer ([@b6-ol-0-0-8836]--[@b8-ol-0-0-8836]).

To investigate the expression of the E-cadherin protein in invasive breast cancer and its possible clinical significance, 450 cases of invasive ductal carcinoma of the breast were assessed. The expression of E-cadherin was detected using immunohistochemistry, and the association between lymph node metastasis, clinicopathological features and molecular typing was analyzed. In addition, the roles of E-cadherin in lymph node metastasis and the prognosis of breast cancer were investigated.

Patients and methods
====================

### Patients

A total of 512 patients with primary invasive ductal carcinoma of the breast were enrolled at the Affiliated Tumor Hospital of Xinjiang Medical University (Urumqi, China) between January 2001 and January 2011. The patients were randomly selected and 62 cases with non-conforming specimens were excluded from the study. All specimens were fixed using 10% formaldehyde at 36--38°C for 6--8 h, embedded in paraffin and sliced into 4-μm continuous pathological sections.

### Case inclusion criteria

Case inclusion criteria were as follows: Diagnosis according to breast pathology; no history of radiotherapy, chemotherapy or endocrine therapy prior to admission; Karnofsky performance status score of ≥80 points and surgery performed with all samples identified by three pathology experts for histopathological identification of breast invasive ductal carcinoma; no other malignancy history; preoperative consent specimens collected and informed consent obtained; and approval provided by the Xinjiang Medical University Affiliated Cancer Hospital Ethics Committee.

### Case exclusion criteria

Case exclusion criteria were as follows: Breast invasive lobular carcinoma and carcinoma *in situ*; and preoperative chemotherapy, radiotherapy or endocrine therapy. In addition, other exclusions were breast cancer metastases and other specific types of breast tumors (sarcoma, micropapillary carcinoma, lymphoma, inflammatory breast cancer, male breast carcinoma and gestational breast cancer).

### Basic information of case data

The breast cancer patients were between 28 and 75 years of age, with a mean age of 49.30±10.48 years, and the median age was 48 years. There were 317 premenopausal patients and 133 postmenopausal patients. All patients were female.

Methods
-------

### Immunohistochemical staining of the SP (streptavidin-peroxidase) method

Breast cancer specimens were treated with dewaxing and hydration, according to the manufacturer\'s protocol for immunohistochemical SP method staining (cat. no. SP0041; Beijing Solarbio Science and Technology Co., Ltd., Beijing, China), and the microwave method was used to repair antigens. Specimens of 30 benign fibroadenoma cases were obtained from patients at the Affiliated Tumor Hospital of Xinjiang Medical University, with a positive result for E-cadherin was considered as a positive control, and five fields of view were randomly selected under the microscope. Each field counted for 100 cells. Patients with benign fibroadenoma were enrolled at the Affiliated Tumor Hospital of Xinjiang Medical University between January 2001 and January 2011. The patients were randomly selected. The patients with benign fibroadenoma were between 19 and 51 years of age, and the median age was 32 years. All patients were female and there were 30 patients in the group.

### Case inclusion criteria

Case inclusion criteria were as follows: Samples from surgery were observed by three pathology experts via histopathological identification to confirm fibroadenoma of the breast; Karnofsky performance status score of ≥80 points; no history of tumors; and no family history of tumors.

### Case exclusion criteria

Case exclusion criteria were as follows: Breast fibroadenoma with a history of breast cancer; breast fibroadenoma with a history of other malignant tumors; and breast fibroadenoma with mastitis disease.

### Standard of E-cadherin staining criteria

The immunohistochemical staining results of the study were determined by three pathologists, and five ×400 magnification visual fields were randomly observed. E-cadherin expression was determined by a semi-quantitative method according to the following score standard for the percentage of cell staining: 0--10%, 0 points, (−); 11--25%, 1 point, (+); 26--50%, 2 points, (++); 51--75%, 3 points, (+++); and \>75%, 4 points, (++++). Those cells with a score of ≤2 were considered to be negative for E-cadherin and those with a score of ≥3 were considered to be positive.

### Follow-up method

Telephone follow-up calls were conducted to identify associated information, the information recorded in the case was approved by the patient. Patient medical records were used to record identity, phone numbers, addresses and other personal information, including postcode, sex and history of breast cancer. Three phone calls were made to follow-up each patient, and for the patients who could not be contacted, their last discharge time was used. The follow-up calendar period was until January 31, 2016, and the follow-up time period was 1--72 months.

Tumor, Node, Metastasis staging of breast cancer was performed according to the American Joint Committee on Cancer Staging of Breast Cancer (7th Edition) ([@b1-ol-0-0-8836]). The histological grading of breast cancer was primarily evaluated according to the degree of glandular tube formation, nuclear polymorphisms and mitosis counts. These three aspects were scored between 3--5 points (level I; differentiation), 6--7 (level II; moderately differentiated) and 8--9 (grade III; poor differentiation) ([@b2-ol-0-0-8836]).

### Statistical analysis

All data were shown as the mean ± standard deviation and analyzed using a univariate analysis, χ^2^test or exact probability method. A survival analysis was performed using the Kaplan-Meier method, with the log-rank test, and the SPSS 18.0 statistical software (SPSS, Inc., Chicago, IL, USA) was used. P\<0.05 indicated that the difference was statistically significant.

Results
=======

### Expression of E-cadherin in benign breast hyperplasia tissue

E-cadherin was mainly distributed in the gland duct epithelium and acinar epithelial cell membrane in the benign breast fibroadenoma samples, and was observed as the positive brownish-yellow granules ([Fig. 1](#f1-ol-0-0-8836){ref-type="fig"}). The 30 cases of breast fibroadenoma were enrolled at the Affiliated Tumor Hospital of Xinjiang Medical University (Urumqi, China) between January 2001 and January 2011. The patients were randomly selected. The 30 cases of breast fibroadenoma were positive for E-cadherin.

### Comparing the expression of E-cadherin in invasive ductal carcinoma of the breast and benign mammary gland hyperplasia

As shown in [Fig. 1](#f1-ol-0-0-8836){ref-type="fig"}, E-cadherin staining was positive in breast epithelial cells and stromal cells (brownish-brown particles; SP, ×400 magnification). The expression of E-cadherin in the membranes of infiltrating breast carcinoma cells is shown in [Fig. 2](#f2-ol-0-0-8836){ref-type="fig"}. The positive expression rate of E-cadherin was 36.44% in the 450 cases of invasive ductal carcinoma. The high expression rate was 77/157 (49.04%) in 157 non-metastatic cancer tissues and 87/293 (29.69%) in 293 lymph nodes with lymph node metastasis. This finding indicated that E-cadherin expression in breast cancer tissue is significantly lower in the lymph node metastasis of breast invasive ductal carcinoma than the breast cancer without lymph node metastasis (χ^2^=16.528, P\<0.001; [Table I](#tI-ol-0-0-8836){ref-type="table"}). The low expression of E-cadherin was associated with metastatic lymph node metastasis.

### Expression of E-cadherin in breast invasive ductal carcinoma and its association with the clinicopathological features of breast cancer

As presented in [Table II](#tII-ol-0-0-8836){ref-type="table"}, the expression of E-cadherin exhibited significant differences with regard to the age of the patient, lymph node metastasis, tumor size, estrogen receptor (ER) expression, molecular classification and tumor cell classification. Patients aged \>60 years were significantly associated with the positive expression of E-cadherin. However, there were no significant differences in tumor stage, whether the patients were menopausal or premenopausal, or the expression of receptor tyrosine-protein kinase erbB-2 and proliferation marker protein Ki-67.

### Expression of E-cadherin in breast invasive ductal carcinoma and its association with the prognosis of breast cancer

As shown in [Tables III](#tIII-ol-0-0-8836){ref-type="table"} and [IV](#tIV-ol-0-0-8836){ref-type="table"}, and [Figs. 3](#f3-ol-0-0-8836){ref-type="fig"} and [4](#f4-ol-0-0-8836){ref-type="fig"}, survival analysis identified that there were significant differences in the expression of E-cadherin in the patients with lymph node metastasis (χ^2^=9.546, *P=*0.002) and in those with TNBC (χ^2^=4.48, P=0.03). The low expression of E-cadherin inpatients with TNBC is associated with poorer prognosis. There was no significant difference in the prognosis of the untreated lymph node group, or the Luminal A, Luminal B or human epidermal growth factor receptor 2 (HER-2)-positive group.

Discussion
==========

The incidence of breast cancer continues to grow, and it is currently the most common form of malignant tumor among Chinese women ([@b3-ol-0-0-8836]). Breast cancer metastasis seriously affects the prognosis of patients and is the leading cause of mortality ([@b4-ol-0-0-8836]). Of those patients who receive an early diagnosis of breast cancer subsequent to receiving adjuvant therapy, \~30% will eventually develop recurrence or metastasis ([@b5-ol-0-0-8836],[@b6-ol-0-0-8836]). Breast cancer recurrence and metastasis are severe clinical problems.

Changes in cell adhesion are the main mechanism of invasion and metastasis of a malignant tumor. Changes in adhesion molecules may reduce the adhesion of tumor cells, contributing to tumor infiltration and metastasis. Therefore, the decline of cell adhesion is an important factor leading to tumor metastasis ([@b7-ol-0-0-8836]).

E-cadherin is a type of cell adhesion glycoprotein; it is not only a tumor cell invasion and metastasis inhibitor, but it is also a normal cell growth inhibitor. Studies have found that when epithelial-mesenchymal transition occurs in cancer cells, E-cadherin expression decreases or shows a functional loss, thus causing decreased cell adhesion, loss of polarity and infiltration of the surrounding tissue growth, and it may be transferred to bone, liver, lung and brain tissue ([@b8-ol-0-0-8836]). E-cadherin has become one of the research hotspots among the cadherin family members. Studies have found that E-cadherin is involved in the early occurrence, infiltration and metastasis of different tumors ([@b9-ol-0-0-8836]--[@b12-ol-0-0-8836]). The expression is of E-cadherin is closely associated with the invasion and metastasis of a number of tumors and their clinical prognoses ([@b13-ol-0-0-8836]--[@b15-ol-0-0-8836]).

The present study results suggested that low expression or deletion of E-cadherin was positively associated with lymph node metastasis. The negative expression rate was significantly higher in breast cancer patients with local lymph node metastasis than in patients without local lymph node metastasis, and the differences were statistically significant. Presumably, under normal circumstances, E-cadherin serves a role in maintaining cell morphology within the body ([@b16-ol-0-0-8836]). The present findings further suggested that E-cadherin was closely associated with the infiltration and metastasis of breast ductal carcinoma and could be used as a marker to predict the lymph node metastasis of invasive ductal carcinoma. The study results suggested that E-cadherin expression was associated with the prognosis of patients with breast cancer. The 5-year survival rate was higher in the E-cadherin-positive group than that in the E-cadherin-negative group in lymph node metastatic invasive ductal carcinoma, and the differences were statistically significant (χ^2^=16.53, P\<0.001). E-cadherin expression was associated with the molecular typing of breast cancer. E-cadherin exhibited low expression in breast cancer and TNBC, which was closely associated with the invasion and metastasis of TNBC. The expression of E-cadherin in HER-2-negative and ER-positive samples was high, indicating that ER-positive expression may be involved in the regulation of E-cadherin expression.

Understanding these mechanisms and further investigating the findings of this study will aid in confirming these results and determining other associated important findings. Further research is required to adequately understand the decrease in cell adhesion.
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![E-cadherin is expressed in benign and malignant breast tissues. (A) E-cadherin expression was positive in breast fibroadenoma (streptavidin peroxidase, ×400 magnification). (B) E-cadherin expression was positive in breast cancer lesions (SP, ×400 magnification). Scale bar, 20 µm.](ol-16-02-1659-g00){#f1-ol-0-0-8836}

![Expression of E-cadherin in breast cancer lesions (immunohistochemical staining, ×400 magnification). (A) No E-cadherin expression (−). (B) Low E-cadherin expression (++). (C) High E-cadherin expression (+++). Scale bar, 20 µm.](ol-16-02-1659-g01){#f2-ol-0-0-8836}

![Expression of E-cadherin and patient prognosis in breast cancer with non-metastatic lymph nodes. (A) Non-breast lymph node metastasis group (n=157 cases). (B) Breast cancer lymph node metastasis group (n=293 cases).](ol-16-02-1659-g02){#f3-ol-0-0-8836}

![Expression of E-cadherin and prognosis of breast cancer patients. (A) Luminal A-type breast cancer group (n=62 cases). (B) Luminal B-type breast cancer group (n=249 cases). (C) Human epidermal growth factor receptor-2-positive breast cancer group (n=47 cases). (D) Triple-negative breast cancer group (n=92 cases).](ol-16-02-1659-g03){#f4-ol-0-0-8836}

###### 

Association between E-cadherin expression and lymph node metastasis.

                          Lymph node metastasis, n (%)                        
  ----------------- ----- ------------------------------ ----------- -------- ------------------------------------------------------
  High expression   164   87 (53.0)                      77 (47.0)   16.528   \<0.001^[a](#tfn2-ol-0-0-8836){ref-type="table-fn"}^
  Low expression    286   206 (72.0)                     80 (28.0)            

E-cadherin -/++ is negative expression, +++/++++ is positive expression. Lymph node metastasis refers to the axillary lymph nodes and sentinel lymph node, and includes lymph node micrometastases, tumor metastatic lesions of \<2.0 mm in diameter, clusters of tumor cells and individual tumor cells.

P\<0.05.

###### 

Expression of E-cadherin in clinicopathological features of breast cancer.

                                                     E-cadherin expression, n                           
  -------------------------------------------- ----- -------------------------- ----- -------- -------- ------------------------------------------------------
  Total patients                               450   164                        286   36.444            
  Age, years                                                                                            
    ≤35                                        87    40                         47    45.977   8.373    0.015^[a](#tfn3-ol-0-0-8836){ref-type="table-fn"}^
    35--60                                     253   95                         158   37.549            
    ≥60                                        110   29                         81    26.364            
  Number of positive lymph nodes No transfer   157   77                         80    49.044   18.796   \<0.001^[a](#tfn3-ol-0-0-8836){ref-type="table-fn"}^
    1--3                                       203   66                         137   32.512            
    ≥4                                         90    21                         69    23.333            
  TNM staging                                                                                           
    I                                          65    20                         45    30.769   2.162    0.339
    II                                         234   94                         140   40.171            
    III                                        151   54                         97    35.762            
  Breast mass size, cm                                                                                  
    ≤2                                         107   53                         54    49.533   10.520   0.005^[a](#tfn3-ol-0-0-8836){ref-type="table-fn"}^
    2--5                                       274   90                         184   32.847            
    ≥5                                         69    21                         48    30.435            
  Menopause                                                                                             
    No                                         317   114                        203   35.962   0.108    0.743
    Yes                                        133   50                         83    37.594            
  c-erbB-2                                                                                              
    Positive                                   85    25                         60    29.411   2.238    0.135
    Negative                                   365   139                        226   38.082            
  ER                                                                                                    
    Positive                                   167   44                         123   26.347   11.688   \<0.001^[a](#tfn3-ol-0-0-8836){ref-type="table-fn"}^
    Negative                                   283   120                        163   42.403            
  Ki-67,%                                                                                               
    ≤14                                        41    20                         21    48.780   2.964    0.085
    \>15                                       409   144                        265   35.208            
  Molecular typing                                                                                      
    Luminal A                                  62    22                         40    35.484   17.466   \<0.001^[a](#tfn3-ol-0-0-8836){ref-type="table-fn"}^
    Luminal B                                  249   84                         165   33.735            
    HER-2-positive                             47    30                         17    63.830            
    Triple-negative                            92    28                         64    30.435            
  Histological grade                                                                                    
    I                                          90    51                         39    56.667   22.770   \<0.001^[a](#tfn3-ol-0-0-8836){ref-type="table-fn"}^
    II                                         258   88                         170   34.109            
    III                                        102   25                         77    24.510            

P\<0.05. TNM, tumor-node-metastasis; c-erb-B2, receptor tyrosine-protein kinase erbB-2; ER, estrogen receptor; Ki-67, proliferation marker protein Ki-67; HER-2, human epidermal growth factor receptor 2.

###### 

Expression of E-cadherin in lymph node metastasis and non-metastasis of breast cancer was analyzed by statistical analysis (Kaplan-Meier method).

                                   Non-breast lymph node metastasis group   Breast cancer lymph node metastasis group                        
  -------------------------------- ---------------------------------------- ------------------------------------------- ------- --- -------- ------------------------------------------------------
  Log-rank (Mantel-Cox)            1                                        3.628                                       0.057   1   9.546    0.002^[a](#tfn4-ol-0-0-8836){ref-type="table-fn"}^
  Breslow (generalized Wilcoxon)   1                                        3.191                                       0.074   1   12.234   \<0.001^[a](#tfn4-ol-0-0-8836){ref-type="table-fn"}^
  Tarone-Ware                      1                                        3.417                                       0.065   1   10.862   0.001^[a](#tfn4-ol-0-0-8836){ref-type="table-fn"}^

P\<0.05. There were no statistically significant differences in the three survival statistic tests in the lymph node metastasis group. There was a significant difference in E-cadherin expression and low expression survival analysis in the lymph node metastasis group. df, degrees of freedom.

###### 

Expression of E-cadherin in different molecular types of breast cancer: Survival analysis (Kaplan-Meier method).

                                       Luminal A   Luminal B   HER-2-positive   Triple-negative                        
  -------------------------------- --- ----------- ----------- ---------------- ----------------- ------ ------ ------ ---------------------------------------------------
  Log-rank (Mantel-Cox)            1   2.87        0.09        4.33             0.04              0.61   0.43   4.48   0.03^[a](#tfn5-ol-0-0-8836){ref-type="table-fn"}^
  Breslow (generalized Wilcoxon)   1   2.87        0.09        3.31             0.07              0.51   0.48   5.42   0.02^[a](#tfn5-ol-0-0-8836){ref-type="table-fn"}^
  Tarone-Ware                      1   2.87        0.09        3.75             0.05              0.51   0.46   5.03   0.02^[a](#tfn5-ol-0-0-8836){ref-type="table-fn"}^

P\<0.05. df, degrees of freedom; HER-2, human epidermal growth factor receptor 2.
